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Objectives: To assess the incidence and rates of hypoglycaemia in patients with type 1 diabetes mellitus (T1DM) or type 2 
diabetes mellitus (T2DM) in the South African cohort of the International Operations Hypoglycaemia Assessment Tool (IO HAT) 
study.
Methods: Patients diagnosed with either T1DM or T2DM, aged ≥ 18 years and treated with insulin for > 12 months, completed self-
assessment questionnaires to record demography, treatment information and hypoglycaemia during a 6-month retrospective 
and 4-week prospective periods (ClinicalTrials.gov: NCT02306681).
Results: In T1DM 76.2% (95% confidence interval [CI] 69.1%, 82.3%) of patients reported hypoglycaemia in the retrospective 
period and 98.2% (95% CI 94.7%, 99.6%) in the prospective period. The corresponding figures for patients with T2DM were 52.2% 
(95% CI 48.6%, 55.9%) and 90.1% (95% CI 87.7%, 92.3%), respectively. Rates of any and severe hypoglycaemia, respectively were 
T1DM 90.7 events per patient year (PPY) (95% CI 85.5, 96.1) and 8.8 events PPY (95% CI 7.2, 10.6) and T2DM 45.7 events PPY (95% 
CI 43.9, 47.5) and 8.9 events PPY (95% CI 8.1, 9.8) during the prospective period. The rates of hypoglycaemia were independent 
of glycated haemoglobin levels.
Conclusions: This is the first patient dataset of self-reported hypoglycaemia in South Africa; results showed that hypoglycaemia 
is under-reported.
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Introduction
Insulin is the mainstay of treatment for patients diagnosed with 
type 1 diabetes mellitus (T1DM) and is often used as an adjunct 
to oral antidiabetic agents in patients with type 2 diabetes 
mellitus (T2DM). Achieving optimum glycaemic control in 
insulin-treated patients with DM is commonly offset by resultant 
hypoglycaemia.1 A report of a workgroup of the American 
Diabetes Association (ADA) and the endocrine society defines 
hypoglycaemia in patients with DM as abnormally low plasma 
glucose concentrations that can expose the patient to potential 
harm.1 Symptoms and signs include tachycardia, tremor, 
sweating, nausea, extreme hunger, numbness, tingling, mood 
changes, irritability, confusion, slurred speech, loss of 
consciousness, weakness, cardiac dysfunction and seizures or 
death.2 These symptoms manifest progressively according to the 
severity of the hypoglycaemia.
The ACCORD and ADVANCE studies concluded that there was no 
evidence to suggest any of the deaths reported were caused 
directly by hypoglycaemia, although patients who experienced 
severe hypoglycaemia did have significantly higher mortality 
rates.3,4 The basis of increased fatal and non-fatal adverse events 
among patients with severe hypoglycaemia is unclear. However, 
it is postulated that hypoglycaemia may be a surrogate measure 
of overall morbidity and disease burden.5 In fact, two studies 
have documented a 3.4- to 4-fold increased risk of death due to 
severe hypoglycaemia.5,6
Recent guidelines on diabetes treatment focused on the need 
for individualised glycated haemoglobin (HbA1c) targets to 
balance reductions in hyperglycaemia with the potential risks of 
hypoglycaemia.7 Hence, HbA1c level is considered as one of the 
key factors in individualising treatment regimens in diabetes 
patients.
In a study conducted in Cape Town, patient decision and health 
systems in South Africa were identified as potential barriers in 
initiating insulin therapy.8 Furthermore, a fear of hypoglycaemia 
is one of the important reasons for the avoidance and delay in 
initiation of insulin therapy.9
Very few studies on hypoglycaemia have thus far been reported 
in South Africa.10 Due to the lack of data on the incidence of 
hypoglycaemia in South Africa the problem may be grossly 
underestimated.
The non-interventional International Operations Hypoglycaemia 
Assessment Tool (IO HAT) study was designed to study the 
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prevalence of hypoglycaemia in insulin-treated DM in 
Bangladesh, Colombia, Egypt, Indonesia, Philippines, Singapore, 
South Africa, Turkey and United Arab Emirates.11 The aim of this 
sub-analysis was to assess the incidence and rates of 
hypoglycaemia in insulin-treated patients with T1DM or T2DM in 
the South African cohort.
Study design and methods
Study design
This was a non-interventional, multicentre, six-month 
retrospective and four-week prospective study of hypoglycaemic 
events using a two-part self-assessment questionnaire (SAQ1 
and SAQ2) and patient diary (PD) for 28 days (Figure 1).
All patients in the South African cohort of the IO HAT study who 
responded to SAQ1 were included in this sub-analysis. Data on 
hypoglycaemia were collected from patients recruited between 
December 15, 2014 and May 14, 2015 across 31 sites in South 
Africa.
Eligible patients were enrolled consecutively during their routine 
clinic appointment with their healthcare provider to avoid 
selection bias. The study was approved by local ethics committees 
and health authorities and carried out in accordance with Good 
Pharmaco-epidemiological Practice and the Declaration of 
Helsinki: Ethical Principles for Medical Research Involving Human 
Patients.12,13
Study population
South African male or female patients aged ≥ 18 years at baseline 
with T1DM or T2DM treated with insulin for more than 12 months, 
ambulatory, and having signed an informed consent form were 
included in the study. Patients who had other issues such as 
illiteracy or inability to complete a written questionnaire were 
excluded from the study. No specific treatments were 
recommended or provided to the patients for their participation 
in the study.
Self-assessment of hypoglycaemia
SAQ1 was used to record baseline demographics, treatment 
information, hypoglycaemia unawareness, and perceptions of 
hypoglycaemia, the history of severe hypoglycaemia over the 
last six months, and any/nocturnal hypoglycaemia over the last 
four weeks and returned at baseline. SAQ2 was used to evaluate 
the history of severe and symptomatic hypoglycaemia, 
healthcare utilisation over the following four weeks after study 
entry and returned at the end of the study. To assist recall, the 
patients were advised to record the hypoglycaemic episodes in 
the PD provided to them. To avoid recall bias, the values in the PD 
were used to calculate incidence of hypoglycaemia in the 
four  weeks after baseline in case the patient recorded fewer 
hypoglycaemic episodes in SAQ2.
Differences in reported hypoglycaemia in the retrospective and 
prospective periods were used to estimate under-reporting.
Patient knowledge of hypoglycaemia was evaluated by assessing 
if their understanding was consistent with the ADA definition of 
hypoglycaemia.1 It was important to assess if they knew what 
hypoglycaemia was before they read the introduction provided 
in the informed consent form. Specific questioning to determine 
if they had symptoms when they had low blood sugar levels 
assessed hypoglycaemia awareness. The response ‘usually’ 
denoted impaired awareness, and ‘occasionally’ or ‘never’ 
denoted severely impaired awareness (unawareness).14 Patients 
rated fear of hypoglycaemia on a scale of 0 (not afraid at all) to 10 
(absolutely terrified).
Study objectives
The primary endpoint of this sub-analysis was to determine the 
percentage of patients experiencing at least one hypoglycaemic 
episode in the four-week prospective periods among insulin-
treated patients with T1DM or T2DM. Difference in rates of any 
and nocturnal hypoglycaemia were compared between the 
four  weeks before baseline and the four  weeks after baseline; 
and rates of severe hypoglycaemia during the six-month 
Figure 1: IO HAT study design. Severe hypoglycaemia: an event requiring assistance of another person to actively administer carbohydrate, glucagon, 
or other resuscitative actions. Non-severe hypoglycaemia: documented symptomatic (symptoms and blood glucose measurement ≤ 3.9 mmol/L 
[70 mg/dL]) and probable symptomatic (symptoms only) hypoglycaemia.
Note: NSH = non-severe hypoglycaemia; SAQ = self-assessment questionnaire; SH = severe hypoglycaemia.
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retrospective and four-week prospective periods. Secondary 
endpoints included the relationship between hypoglycaemia 
and HbA1c levels, duration of diabetes, type of insulin therapy, 
patient’s knowledge of hypoglycaemia, fear of hypoglycaemia, 
patient actions as a result of hypoglycaemia, hypoglycaemia 
unawareness as a factor and the impact of hypoglycaemia on 
healthcare utilisation.
Categorisation of hypoglycaemia
Categories of hypoglycaemia recorded in SAQ1, SAQ2, and the 
PD confirmed that a hypoglycaemic episode was defined as 
blood glucose (BG) < 3.1  mmol/l not requiring assistance of 
another person and a severe hypoglycaemic episode as any 
hypoglycaemic event requiring assistance of another person to 
administer carbohydrate, glucagon or other resuscitative actions 
and/or hospitalisation.1 Nocturnal hypoglycaemia is any event 
occurring between midnight and six o’clock in the morning. A 
combined measure of any hypoglycaemic episode is the sum of 
all individual hypoglycaemic events of any category and this was 
calculated based on PD, SAQ1, and SAQ2 entries.
Statistical analysis
For the primary endpoint, the percentage of patients who 
experienced at least one hypoglycaemic episode in the four-
week prospective periods among insulin-treated patients with 
T1DM or T2DM was calculated together with 95% confidence 
interval (CI), with the percentage presumed to predict a binomial 
distribution. Incidence rates of hypoglycaemia were reported as 
events per patient-year (PPY), calculated as the total number of 
events divided by total follow-up time in patient-years together 
with 95% CI.
Statistical tests were two-sided and regarded as exploratory, 
with the criterion for statistical significance set at p < 0.05. No 
adjustments were made for multiple comparisons. No imputation 
of missing data was performed, as the majority of analyses were 
descriptive in nature. Baseline refers to data collected using the 
SAQ1; follow-up refers to data collected using the SAQ2 and, 
where applicable, the PD.
Results
Demographic and clinical characteristics of study 
subjects
A total of 915 patients were enrolled from study sites in South 
Africa (T1DM, n = 173; T2DM, n = 742) and completed SAQ1. Of 
these, 864 patients (T1DM, n = 168; T2DM, n = 696) completed 
SAQ2 and 812 patients (T1DM, n = 160; T2DM, n = 652) completed 
the PD in the prospective period.
Descriptive baseline characteristics of the South African cohort 
are shown in Table 1.
Primary endpoints
Any hypoglycaemic episode
During the prospective period a higher percentage of patients 
(T1DM 98.2% [95% CI 94.7%, 99.6%]; T2DM 90.1% [95% CI 87.7%, 
92.3%]) reported at least one hypoglycaemic event compared 
with patients (T1DM 76.2% [95% CI 69.1%, 82.3%]; T2DM 52.2% 
[95% CI 48.6%, 55.9%]) in the retrospective period. In patients 
with T1DM, the rates for any hypoglycaemia increased from 53.8 
events PPY (95% CI 49.9, 57.9) in the four-week retrospective 
period, to 90.7 events PPY (95% CI 85.5, 96.1) in the four-week 
prospective period. In patients with T2DM, the rates for any 
Table 1: Patient demographic characteristics
*Data were presented as mean (SD) unless otherwise stated; SD= standard 
deviation; BMI = body mass index; FBG = fasting blood glucose; HbA1c = glycated 
haemoglobin; PPG = postprandial glucose; N = total number of patients 
participating; **percentages based on number of patients with evaluable data;  
n = number of subjects in the data subset who responded to the set of questions; 
SGLT2 = sodium-glucose co-transporter-2; T1DM = type 1 diabetes mellitus;  
T2DM = type 2 diabetes mellitus.
Characteristics T1DM (N = 173) T2DM (N = 742)
Age, years* 40.0 (13.4) 57.1 (10.5)
Male/female (%) 46.8/53.2 51.94/47.4
Duration of diabetes, years* 16.9 (12.0) 13.5 (7.80)
Duration of insulin use, years* 16.4 (12.1) 7.4 (5.5)
HbA1c, %* 8.2 (1.6) 8.5 (1.8)
FBG (mmol/l)* 8.4 (4.0) 7.9 (2.7)
PPG (mmol/l)* 9.5 (3.6) 9.3 (3.2)
BMI (kg/m2)* 26.3 (5.3) 32.3 (6.0)
Previous medical illnesses (%)**
 Neuropathy 20.8 28.3
 Retinopathy 22.0 16.7
 Nephropathy 8.1 10.1
 Peripheral vascular disease 12.1 10.4
 Angina 1.7 7.8
 Myocardial infarction 1.2 7.1
 None 63.0 50.7
Oral antidiabetic medications, 
n (%)**
 Amylin analogue 0 1 (0.1)
 Alpha-glucosidase inhibitor 1 (0.6) 3 (0.4)
 Metformin 23 (13.3) 606 (81.7)
 Bile acid sequestrant 1 (0.6) 2 (0.3)
 Dipeptydyl peptidase-IV 1 (0.60 20 (2.7)
 Glucagon-like peptide-1 4 (2.3) 22 (3.0)
 Metiglinides/glinides 0 (0.0) 1 (0.1)
 SGLT2 inhibitors 0 (0.0) 0
 Sulfonylurea 1 (0.6) 109 (14.7)
 Thiazoledinediones/glitazones 1 (0.6) 14 (1.9)
 Other 1 (0.6) 3 (0.4)
 None 140 (80.9) 95 (12.8)
 Missing 6 (3.5) 20 (2.7)
Insulin treatment, n (%)**
 Short-acting 29 (16.8) 13 (1.8)
 Long-acting 13 (7.5) 168 (22.6)
 Pre-mix 22 (12.7) 345 (46.5)
 Both short and long acting 105 (60.7) 194 (26.1)
 Both short acting and pre-mix 1 (0.6) 8 (1.1)
 Both long acting and pre-mix 1 (0.6) 2 (0.3)
 Short and long acting and 
pre-mix
0 1 (0.1)
 Missing 2 (1.2) 11 (1.5)
Checks blood sugar levels with 
own glucose meter, n (%)**
 Yes 169 (97.7) 697 (93.9)
 No 3 (1.7) 25 (3.4)
 Not sure 0 8 (1.1)
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for patients with T2DM. In the four-week prospective period, 
40.0% (95% CI 32.3%, 48.0%) of patients with T1DM and 47.8% 
(95% CI 43.9%, 51.6%) of patients with T2DM experienced at least 
one severe hypoglycaemic event. The hypoglycaemia rates were 
8.8 events PPY (95% CI 7.2, 10.6) for patients with T1DM and 8.9 
events PPY (95% CI 8.1, 9.8) for patients with T2DM (see Figure 2).
Secondary endpoints
Hypoglycaemia vs. duration of diabetes
For patients with T2DM, longer duration of diabetes was 
associated with an overall increase in percentage of patients 
with any and nocturnal hypoglycaemic events from 88.3% to 
89.7% and from 17.7% to 25.5%, respectively, during the 
prospective period and from 51.1% to 60.5% and from 15.3% to 
28.9%, respectively, during the retrospective period. For patients 
with T1DM, longer duration of diabetes was associated with an 
overall decrease in percentage of patients with any 
hypoglycaemic event (from 100.0% to 95.5%) during the 
prospective period and an overall increase in percentage of 
hypoglycaemia increased from 21.3 events PPY (95% CI 20.1, 
22.5) in the four-week retrospective period, to 45.7 events PPY 
(95% CI 43.9, 47.5) in the four-week prospective period (Figure 2).
Nocturnal hypoglycaemic episode
In the four-week retrospective period, 47.0% (95% CI 39.2%, 
54.9%) of patients with T1DM and 20.9% (95% CI 18.0%, 24.1%) 
of patients with T2DM experienced at least one nocturnal event. 
In the four-week prospective period, 42.7% (95% CI 34.8%, 
50.8%) of patients with T1DM and 21.0% (95% CI 18.0%, 24.3%) 
of patients with T2DM experienced nocturnal hypoglycaemia. 
The hypoglycaemia rate was comparable between the 
retrospective and prospective periods for patients with T1DM 
and T2DM (p = 0.044 and p = 0.093, respectively) (see Figure 2).
Severe hypoglycaemic episode
In the six-month retrospective period, 40.0% (95% CI 32.6%, 
47.8%) of patients with T1DM and 37.7% (95% CI 34.2%, 41.3%) of 
patients with T2DM experienced at least one hypoglycaemic 
event. The hypoglycaemia rates were 6.0 events PPY (95% CI 5.5, 
6.6) for patients with T1DM and 2.2 events PPY (95% CI 2.1, 2.4) 
(a) (b)
Figure 2: Percentage of patients and rates of hypoglycaemia during retrospective and prospective periods: (a) T1DM, (b) T2DM. ‘Any’ and ‘Nocturnal’ 
hypoglycaemia based on four-week period for both retrospective and prospective analyses. *Retrospective data based on six-month period and 
prospective data based on four-week period. RR = rate ratio; T1DM = type 1 diabetes mellitus, T2DM = type 2 diabetes mellitus.
(a) (b)
Figure 3: Percentage of patients and rates of severe hypoglycaemia by duration of diabetes: (a) T1DM, (b) T2DM. Percentages represent percentage of 
patients with hypoglycaemia in each quartile. Data for severe hypoglycaemia based on the six months before baseline for the retrospective period and 
the four weeks after baseline for the prospective period; PPY = per patient-year; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
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four weeks after baseline period compared with the four weeks 
before baseline period.
A scatter plot with regression line and 95% CI for patients with 
T1DM or T2DM showed no association between HbA1c levels and 
hypoglycaemic events (data not shown).
Hypoglycaemia vs. type of insulin used
There were higher reported rates of any and severe 
hypoglycaemia in patients with both T1DM and T2DM in the 
prospective period, irrespective of treatment, compared with the 
retrospective period. On the other hand, rates of nocturnal 
hypoglycaemia generally decreased in the four-week prospective 
period compared with the four-week retrospective period in 
patients with T1DM and T2DM.
The hypoglycaemic rates in the any hypoglycaemia group were 
highest in patients with T1DM on short-acting regimens during 
the retrospective and prospective periods. Rates of ‘any’ 
hypoglycaemia were lowest in patients with T2DM on long-
acting insulin regimens during both the retrospective and 
prospective periods (Figure 5).
patients with any hypoglycaemic event (from 69.4% to 82.9%) 
during the retrospective period.
For patients with T2DM, there was an overall increase in 
percentage of patients with severe hypoglycaemia from 40.9% 
to 45.2% during the prospective period and from 33.1% to 41.4% 
during the retrospective period in those with a longer duration 
of diabetes (Figure 3). In contrast, there was an overall decrease 
in percentage of patients with severe hypoglycaemia in T1DM 
patients from 48.6% to 36.4% and from 41.7% to 39.1% during 
the prospective and retrospective periods, respectively, in those 
with longer duration of diabetes.
Hypoglycaemia vs. HbA1c levels
There was no association observed between the percentages of 
patients with any or nocturnal or severe hypoglycaemia and 
baseline HbA1c during the four weeks before and after baseline 
periods. For both T1DM and T2DM patients, a higher proportion 
of patients in the HbA1c > 9.0% category experienced severe 
hypoglycaemia compared with those with an HbA1c between 
7.0% and 9.0%, and HbA1c < 7.0% categories during the four 
weeks after baseline period (Figure 4). A higher proportion of 
patients experienced severe hypoglycaemia (Figure 4) in the 
(a) (b)
Figure 4: Percentage of patients with severe hypoglycaemia by baseline HbA1c: (a) T1DM, (b) T2DM. HbA1c = haemoglobin A1C = type 1 diabetes 
mellitus; T2DM = type 2 diabetes mellitus.
(a) (b)
Figure 5: Estimated rate of any, nocturnal, and severe hypoglycaemic event during retrospective and prospective period, by insulin regimen in T1DM 
and T2DM. †Data based on four-week period for both retrospective and prospective analyses; ‡Retrospective data based on six-month period and 
prospective data based on four-week period. S+L = short-acting and long-acting insulin.
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hypoglycaemic events (data not shown).
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Figure 5: Estimated rate of any, nocturnal, and severe hypoglycaemic event during retrospective and prospective period, by insulin regimen in T1DM 
and T2DM. †Data based on four-week period for both retrospective and prospective analyses; ‡Retrospective data based on six-month period and 
prospective data based on four-week period. S+L = short-acting and long-acting insulin.
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periods were: increased BG monitoring (T1DM/T2DM 
49.7%/32.3%; 36.3%/26.6%, respectively), requiring any form of 
medical assistance (T1DM/T2DM 45.7%/31.7%; 14.3%/15.2%, 
respectively), and consulting a doctor or nurse (T1DM/T2DM 
45.1%/30.5%; 14.3%/14.7%, respectively) (Table 2).
Hypoglycaemia unawareness
A higher proportion of patients had normal awareness, in which 
symptoms were ‘always’ or ‘usually’ experienced in combination 
with a low BG measurement and was reported by 66.5% and 
43.7% of patients with T1DM and T2DM, respectively. Impaired 
hypoglycaemia awareness was observed amongst 30.6% of 
patients with T1DM and 45.8% of patients with T2DM as they 
were only occasionally aware of symptoms when experiencing a 
low BG measurement. Severe impairment (defined as never 
experiencing symptoms when having a low glucose 
measurement) was seen in 1.2% of the T1DM group and 5.5% of 
the T2DM group.
Healthcare utilisation
The impact of hypoglycaemic events on the medical system was 
compared in patients with T1DM vs. T2DM, during the six-month 
retrospective period and the four-week prospective period. This 
included telephone contacts with a healthcare team member 
(14.6%/9.5% vs. 3.1%/4.3%), additional clinic appointments 
(5.1%/2.9% vs. 0.6%/2.4%) and a hypoglycaemic event leading to 
Patients with T1DM or T2DM treated with varying insulin 
regimens reported varying rates of severe hypoglycaemia, 
during the retrospective and prospective periods (Figure 5).
Other secondary outcomes
Patient knowledge of hypoglycaemia (before and 
after entering the study)
Most patients with T1DM (90.3%) compared with T2DM (73.8%) 
knew the overall definition of hypoglycaemia before reading the 
definition in SAQ1. A higher number of patients with T2DM 
(36.0%) than T1DM (34.1%) defined hypoglycaemia based on 
symptoms only (Table 2).
Patient fear of hypoglycaemia
The percentage of patients with T1DM or T2DM who rated fear of 
hypoglycaemia based on a scale is enumerated in Table 2. At 
baseline, absence of notable differences in mean score (standard 
deviation) between patients with T1DM or T2DM (5.5 [3.1] vs. 5.1 
[3.4], respectively), implied similarity between patients with 
T1DM or T2DM with regard to fear of hypoglycaemia.
Patient actions as a result of hypoglycaemia
A higher proportion of patients with T1DM compared with T2DM 
reported taking action following hypoglycaemia. The most 
common responses during the retrospective and prospective 
Table 2: Patient perspectives on hypoglycaemia
*Either symptoms or BG measurement; **Both symptoms and BG measurements; BG = blood glucose; N = total number of subjects participating; #Percentages based on 
number of patients with evaluable data; SAQ = self-assessment questionnaire; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
Item T1DM (N = 173) T2DM (N = 742)
Knew what hypoglycaemia was at baseline before SAQ1 (%)# 90.3 73.8
Defined hypoglycaemia based on (%)#:
Symptoms only 34.1 36.0
BG measurement only 6.4 8.9
Either* 13.9 8.0
Both** 40.5 32.3
Fear of hypoglycaemia (scale of 0 to 10; %)#










10 = absolutely terrified 13.9 17.8
Patient response to hypoglycaemia (%)# Retrospective (n = 173) Prospective (n = 742) Retrospective (n = 168) Prospective (n = 696)
Consulted their doctor/nurse 45.1 14.3 30.5 14.7
Required any form of medical assistance 45.7 14.3 31.7 15.2
Increased calorie intake 22.4 31.0 24.1 17.7
Avoided physical exercise 7.5 4.2 7.5 5.5
Reduced insulin dose 27.6 26.2 14.6 11.1
Skipped insulin injections 11.6 8.3 8.6 4.7
Increased BG monitoring 49.7 36.3 32.3 26.6
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may have received help from their family members when they 
experienced hypoglycaemia. Diabetes patients unintentionally 
may have reported these events as severe based on the ADA 
definition of severe hypoglycaemia.1 This oversight may have led 
to higher reporting and highlights an additional need for patient 
education.
The global HAT reported that severe hypoglycaemia rates did 
not appear to be significantly associated with the HbA1c level in 
both T1DM and T2DM (p = 0.211 vs. p = 0.082, respectively).19 In 
fact, two recent studies have established that the association of 
HbA1c with hypoglycaemia in T1DM has decreased in recent 
years, suggesting that risk of hypoglycaemia is common at all 
levels of glycaemic control.21–23
The majority of patients with T1DM (97.7%) or T2DM (93.9%) in 
the South African cohort regularly checked blood sugar levels 
with home glucose monitoring and around half the study 
population had hypoglycaemic awareness. Furthermore, there 
was a large difference between the percentage of patients with 
T1DM and T2DM (90.3% vs. 73.5%, respectively) in terms of 
patient knowledge of hypoglycaemia before and after entering 
the study.
These results further strengthen the evidence that management 
of hypoglycaemic episodes involves increased healthcare costs 
(both direct and indirect) in the form of increased doctor or nurse 
consultations, requirement for any medical assistance, and 
increased frequency of home BG monitoring. This sub-group 
analysis of the IO HAT study also demonstrates the significant 
effect of hypoglycaemia on the healthcare system and confirms 
that hypoglycaemia has a negative impact in diabetes patients.24
The ease with which self-reported hypoglycaemia data are 
obtained makes such a study less expensive and less invasive in 
collecting a large amount of data, from a large study population.11 
The PD and SAQ2 were used in the prospective period to reduce 
recall bias, with possible chances of overestimation of rate in the 
prospective period. The subjective approach of recording a 
hypoglycaemic episode by either symptoms or BG testing alone, 
or in combination, may be considered a strength as well as a 
limitation of the study.
These results demonstrate that hypoglycaemia is under-reported 
and more widespread than previously believed in both T1DM 
and T2DM patients in South Africa. Patients reported higher rates 
of hypoglycaemia (especially severe) during the prospective 
period. This could potentially be due to recall bias during the 
retrospective study period.
The results from this sub-group analysis can help eliminate 
current obstacles to insulin therapy observed in South Africa by 
educating patients on signs and symptoms of hypoglycaemia 
and by optimising healthcare resources such that good 
glycaemic control is achieved with a low risk of hypoglycaemia.
In conclusion, results from this sub-group analysis showed that 
hypoglycaemia might be under-reported in insulin-treated 
patients in South Africa. Therefore, it is vitally important to 
provide continuous medical education programmes to 
healthcare providers and patients in the African region.
Funding – Novo Nordisk provided financial support for the 
conduct of the research. Novo Nordisk was involved in the study 
hospital admission (7.6%/3.6% vs. 3.8%/2.7%). Results showed 
that the impact was slightly higher during the six-month 
retrospective period than in the four-week prospective period 
(both T1DM and T2DM).
Discussion
This is the first data set of self-reported hypoglycaemia that 
evaluated hypoglycaemia incidence and rates in insulin-treated 
patients with T1DM or T2DM in a South African cohort.
Data from this sub-group analysis showed that the percentage of 
patients who reported at least one hypoglycaemic event was 
higher during the prospective period of the study than during 
the retrospective period. It may be use of the PD to record the 
events in the prospective period that helped improve the recall 
of events. Similarly, the retrospective data were recorded at 
baseline by SAQs and may be biased due to failure to recall the 
events.
In contrast, a higher proportion of patients reported nocturnal 
hypoglycaemia during the retrospective period than during the 
prospective period. Patients may have experienced increased 
fear of nocturnal hypoglycaemia, which might be the reason for 
a better recall of such episodes in the retrospective period.
This study has shown an increasing rate of any hypoglycaemic 
event from the retrospective period to the prospective period in 
patients with T1DM within this sub-group analysis of IO HAT 
(53.8 events PPY to 90.7 events PPY). The reported rates for this 
sub-group analysis were much higher than the reported rates 
from another cross-sectional study with adult T1DM and also 
higher than the rates from previous observational studies in 
T1DM or T2DM.15–17
Patients with T2DM within this sub-group of IO HAT also reported 
increasing rates for any hypoglycaemic event from the 
retrospective to the prospective period (21.3 events PPY to 45.7 
events PPY), which were also much higher than the rates 
reported in the Veterans Affairs Diabetes Trial and PREDICTIVE 
trials.16,18
Rates of severe hypoglycaemia in patients with T1DM or T2DM 
were higher than previously reported rates from RCTs and 
observational studies, but are aligned with those of the recent 
global HAT study.19 It has been established that severe 
hypoglycaemia has an annual incidence of 1.0–1.7 events PPY.20
Overall, higher reporting of hypoglycaemia in the prospective 
period may be due to the design of the study itself, as study tools 
like SAQs and PDs reinforced patient knowledge about 
hypoglycaemia during the prospective period.
A higher percentage (40%) of patients with T1DM experienced at 
least one severe hypoglycaemic event during both the six-month 
retrospective period and four-week prospective period. Similarly, 
a higher percentage of patients with T2DM experienced at least 
one severe hypoglycaemic event during both the six-month 
retrospective period and four-week prospective period (37.7% 
and 47.8%, respectively). It has been established that 30–40% of 
patients with diabetes experience a severe hypoglycaemic event 
annually.20
The higher incidences may reflect the real-life scenario of people 
with diabetes in South Africa. For instance, irrespective of the 
severity of the symptoms or BG measurements, diabetes patients 
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